Sun Taps Mitsubishi For Ex-Novartis Japan Portfolio
Sun has now found a commercial partner in Japan for a bundle of mature products the Indian firm acquired from Novartis earlier this year, in an alliance expected to rapidly boost its presence in this key market and which some say might be expanded.
You may also be interested in...
With Phase III data in 2,800 patients for reducing frown lines, ReVance anticipates filing RT002 for US approval in 2019. ABL licenses two bispecific antibody candidates to TRIGR, while Sun looks to expand in dermatology with Pola buyout.
Astellas has joined the growing ranks of research-based pharma firms offloading their older products in Japan, amid rising pricing and generic pressures and an increasing desire to focus on innovation.
Sun Pharmaceutical Industries Ltd, India’s biggest drug firm, has struck a $175m deal to buy the branded skin cancer drug Odomzo from Novartis, continuing a drive to bulk up on higher-margin specialty products in the face of stiff pricing pressure on the generic front.